Director Wu Tong's Team:

Exploration and Improvement in Second Allogeneic Hematopoietic Stem Cell Transplantation.Clinically,some patients still relapse after transplantation.Through our clinical practice,50%to 60%of patients with relapsed B-ALL after transplantation can achieve long-term disease-free survival through sequential CAR-T therapy targeting two antigens.However,for cases where CAR-T therapy is less effective,the duration of CAR-T is too short,the disease has high-risk factors,the donor from the first transplant is suboptimal,or there is multifocal extramedullary leukemia,a second transplant is still required after CAR-T therapy.Internationally,the disease-free survival rate for second transplants is 20%to 30%,with transplant-related mortality at 30%to 40%,and a relapse rate of 30%to 40%.Thus,improving the success rate of second transplants is a challenge that the Bo Ren transplant team is dedicated to solving.To reduce transplant-related mortality,the transplant team has explored and optimized reduced-toxicity,individualized preconditioning regimens and combined this with familial analysis of cancer susceptibility genes to optimize donor selection.Research data show that Bo Ren's transplant team has achieved a 72.5%disease-free survival rate for second transplants,far exceeding the international level and similar to the results of the first transplant;moreover,the transplant-related mortality rate for Boren's team's second transplants is only 2.3%,significantly lower than international reports.Relapse is a critical issue to prevent and treat for patients undergoing a second transplant,so we have also explored a variety of effective maintenance treatment schemes,reducing the relapse rate to 25%.

Exploration in Elderly Transplantation.With the innovation in concepts,the development of transplantation technology,and the advancement of supportive treatments,the age of transplant patients is no longer an absolute"no-go zone".For example,the latest treatment guidelines for AML by the European Leukemia Network(ELN)suggest an upper age limit of 80 years for elderly allogeneic transplantation.Internationally,the disease-free survival rate for elderly AML patients after transplantation is around 50%,whereas our team's elderly transplants have cured about 2/3 of patients,a result that approaches the data for younger transplant patients and is unachievable with traditional chemotherapy.

Transplant Exploration Work for Other Hematologic Diseases.For diseases such as aplastic anemia,hemophagocytic syndrome,chronic active EB virus infection,NK/T-cell lymphoma,etc.,the Boren transplant team has also accumulated a lot of experience and achieved very good overall treatment effects.